Inhibiting PRRs or their downstream signaling pathways may thus represent a therapeutic strategy to reduce MMP-3 activation and mitigate the progression of both AS and atherosclerosis [52,53,58,59,60,61]. The gene discussed is MMP3; the disease is atherosclerosis.